REPLACEMENT THERAPY BEFORE SURGERY OF FVII & FXI DEFICIENT PATIENTS
|
16:30-18:30
|
PARALLEL SESSION VI: Replacement therapy before surgery of FVII & FXI deficient patients
|
|
Chairpersons
|
P.M. Mannucci, Italy
B. Brenner, Israel
|
| 16:30 |
Debate: Replacement therapy before surgery of FVII & FXI deficient patients
Yes: P. Bolton-Maggs, UK
Low dose of rFVIIa for both: O. Salomon, Israel
Discussion |
| 17:20 |
Debate: Prevention and treatment of bleeding in liver disease - should hemostatic agents be used?
Yes: T. Lisman, Netherlands
No: P. M. Mannucci, Italy
Discussion
|
| 18:10 |
Oral Presentation:
THROMBIN GENERATION AND BLEEDING PHENOTYPE IN PATIENTS WITH MILD HEMOPHILIA A WITH DISCREPANT FVIII ASSAYS
E. Santagostino, Italy
|
SATURDAY, NOVEMBER 1, 2014
IMMUNE THROMBOCYTOPENIA; BLEEDING COMPLICATIONS OF NEW ORAL ANTICOAGULANTS
| 13:30-15:30 |
PLENARY SESSION IX: Immune thrombocytopenia; Bleeding complications of new oral anticoagulants
|
| Chairpersons |
F. Peyvandi, Italy
D. Varon, Israel
|
| 13:30 |
Debate: The role of thrombopoietics in ITP
1st line: J. Bussel, USA
3rd line: M. Cattaneo, Italy
Discussion
|
| 14:30 |
State of the Art: Bleeding associated with new oral anticoagulants - assessing the risk and management
D. Varon, Israel
|
| 15:10 |
STRATEGIC MANAGEMENT PLAN TO SUCCESSFULLY IMPLEMENT NEW ORAL ANTICOAGULANTS (NOAS) IN ANTICOAGULATED PATIENTS 2010-2014
A. González Argüello, Spain |
| 15:30 |
Coffee break and poster viewing
|
PLASMA DERIVED VS RECOMBINANT FACTOR VIII CONCENTRATES
| 16:00-18:00 |
PARALLEL SESSION XI: Plasma derived versus recombinant factor VIII concentrates
|
| Chairpersons |
G. Kenet, Israel
F. Peyvandi, Italy
|
| 16:00 |
Debate: Plasma derived versus recombinant factor VIII concentrates: Which one to choose?
P. Peyvandi, Italy
P. Giangrande, UK
Discussion
|
| 16:50 |
State of the Art:
The role of recombinant factor VIIa versus FEIBA in hemophilia with inhibitors
G. Kenet, Israel
|
| 17:10 |
State of the Art:
Can global assays be used to predict response to hemostatic agents?
Y. Dargaud, France
|
| 17:30 |
Oral Presentation:
3-YEAR RESULTS FROM SPINART: PROLONGED REDUCTION OF BLEEDING WITH PROPHYLAXIS USING BAYER’S SUCROSE-FORMULATED RECOMBINANT FACTOR VIII
W. Hong, USA
|
| 17:45 |
Oral Presentation:
EFFICACY OF PROPHYLAXIS USING A PHENOTYPE-GUIDED DOSING STRATEGY WITH BAY 94-9027: RESULTS OF A PHASE 2/3 MULTICENTER, PARTIALLY RANDOMIZED, OPEN-LABEL TRIAL (PROTECT VIII)
L. Michaels, USA
|
